Literature DB >> 26275564

C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population.

Antonino Cannas1, Paolo Solla2, Giuseppe Borghero2, Gian Luca Floris2, Adriano Chio3, Marcello Mario Mascia2, Nicola Modugno4, Antonella Muroni2, Gianni Orofino2, Francesca Di Stefano2, Andrea Calvo3, Cristina Moglia3, Gabriella Restagno3, Mario Meloni2, Rita Farris2, Daniela Ciaccio2, Roberta Puddu2, Melisa Iris Vacca2, Rosanna Melis2, Maria Rita Murru5, Stefania Tranquilli5, Daniela Corongiu5, Marcella Rolesu5, Stefania Cuccu5, Maria Giovanna Marrosu5, Francesco Marrosu2.   

Abstract

The hexanucleotide repeat expansion GGGGCC in the C9ORF72 gene larger than 30 repeats has been identified as a major genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Recent papers investigated the possible pathogenic role and associated clinical phenotypes of intermediate C9ORF72 repeat expansion ranging between 20 and 30 repeats. Some studies suggested its pathogenicity for typical Parkinson's disease (PD), atypical parkinsonian syndromes, FTD with/without parkinsonism, and ALS with/without parkinsonism or with/without dementia. In our study, we aimed to screen patients affected by atypical parkinsonian syndromes or PD complicated by psychosis or dementia for the presence of C9ORF72 repeat expansions, and in unrelated age- and sex-matched healthy controls. Consecutive unrelated patients with atypical parkinsonian syndromes and patients with PD complicated by psychosis or dementia were included in this study. Atypical parkinsonian syndromes were further divided into two groups: one with patients who met the criteria for the classic forms of atypical parkinsonism [multiple system atrophy (MSA), Lewy body disease (LBD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)] ;and patients who did not meet the above criteria, named non-classical atypical parkinsonism with or without dementia. Ninety-two unrelated patients (48 men, 44 women) were enrolled. None of the patients was found to be carriers of C9ORF72 repeat expansions with more than 30 repeats. Intermediate 20-30 repeat expansions were detected in four female patients (4.3 %). Three of them presented clinical features of atypical parkinsonian syndromes, two with non-classical atypical parkinsonism and dementia FTD-like, and one with non-classical atypical parkinsonism without dementia. The other patient presented clinical features of typical PD complicated by psychosis. Among 121 control subjects, none presented long or short expansion for the C9ORF72 gene. Our findings seem to support the hypothesis that the hexanucleotide expansions of C9ORF72 gene with intermediate repetitions between 20 and 29 repetitions could be associated with typical PD with psychosis or dementia and atypical parkinsonisms with dementia (non-classical atypical parkinsonism with dementia FTD-like) or without dementia (non-classical atypical parkinsonism upper MND-like), although the causal relationship is still unclear. In these latter patients, parkinsonism, more or less levodopa responsive, constituted the symptomatological central core at onset.

Entities:  

Keywords:  Atypical parkinsonian syndromes; C9ORF72 short expansion; Parkinson’s disease

Mesh:

Substances:

Year:  2015        PMID: 26275564     DOI: 10.1007/s00415-015-7873-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Enhancements and modifications of primer design program Primer3.

Authors:  Triinu Koressaar; Maido Remm
Journal:  Bioinformatics       Date:  2007-03-22       Impact factor: 6.937

2.  Investigation of C9orf72 repeat expansions in Parkinson's disease.

Authors:  Hussein Daoud; Anne Noreau; Daniel Rochefort; Gabriel Paquin-Lanthier; Maude Turcotte Gauthier; Pierre Provencher; Emmanuelle Pourcher; Nicolas Dupré; Sylvain Chouinard; Nicolas Jodoin; Valérie Soland; Edward A Fon; Patrick A Dion; Guy A Rouleau
Journal:  Neurobiol Aging       Date:  2012-12-27       Impact factor: 4.673

3.  Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72.

Authors:  Rodolfo Savica; Anahita Adeli; Prashanthi Vemuri; David S Knopman; Mariely Dejesus-Hernandez; Rosa Rademakers; Julie A Fields; Jennifer Whitwell; Clifford R Jack; Val Lowe; Ronald C Petersen; Bradley F Boeve
Journal:  Arch Neurol       Date:  2012-09

4.  Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease.

Authors:  S G Lindquist; M Duno; M Batbayli; A Puschmann; H Braendgaard; S Mardosiene; K Svenstrup; L H Pinborg; K Vestergaard; L E Hjermind; J Stokholm; B B Andersen; P Johannsen; J E Nielsen
Journal:  Clin Genet       Date:  2012-07-04       Impact factor: 4.438

5.  Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype?

Authors:  Gianluca Floris; Giuseppe Borghero; Antonino Cannas; Francesca Di Stefano; Emanuela Costantino; Maria R Murru; Maura Brunetti; Gabriella Restagno; Bryan J Traynor; Maria G Marrosu; Adriano Chiò; Francesco Marrosu
Journal:  J Neurol       Date:  2012-02-10       Impact factor: 4.849

6.  Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease.

Authors:  Karen Nuytemans; Vanessa Inchausti; Gary W Beecham; Liyong Wang; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Deborah C Mash; Matthew P Frosch; Tatiana M Foroud; Lawrence S Honig; Thomas J Montine; Ted M Dawson; Eden R Martin; William K Scott; Jeffery M Vance
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

7.  Parkinson disease is not associated with C9ORF72 repeat expansions.

Authors:  Matthew B Harms; Drexel Neumann; Bruno A Benitez; Breanna Cooper; David Carrell; Brad A Racette; Joel S Perlmutter; Alison Goate; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2012-10-30       Impact factor: 4.673

8.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

9.  C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.

Authors:  Davina J Hensman Moss; Mark Poulter; Jon Beck; Jason Hehir; James M Polke; Tracy Campbell; Garry Adamson; Ese Mudanohwo; Peter McColgan; Andrea Haworth; Edward J Wild; Mary G Sweeney; Henry Houlden; Simon Mead; Sarah J Tabrizi
Journal:  Neurology       Date:  2013-12-20       Impact factor: 9.910

10.  C9orf72 repeat expansions are restricted to the ALS-FTD spectrum.

Authors:  Nicola Ticozzi; Cinzia Tiloca; Daniela Calini; Stella Gagliardi; Alessandra Altieri; Claudia Colombrita; Cristina Cereda; Antonia Ratti; Gianni Pezzoli; Barbara Borroni; Stefano Goldwurm; Alessandro Padovani; Vincenzo Silani
Journal:  Neurobiol Aging       Date:  2013-10-02       Impact factor: 4.673

View more
  8 in total

1.  C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy.

Authors:  Christopher P Cali; Maribel Patino; Yee Kit Tai; Wan Yun Ho; Catriona A McLean; Christopher M Morris; William W Seeley; Bruce L Miller; Carles Gaig; Jean Paul G Vonsattel; Charles L White; Sigrun Roeber; Hans Kretzschmar; Juan C Troncoso; Claire Troakes; Marla Gearing; Bernardino Ghetti; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Kin Y Mok; Helen Ling; Dennis W Dickson; Gerard D Schellenberg; Shuo-Chien Ling; Edward B Lee
Journal:  Acta Neuropathol       Date:  2019-07-20       Impact factor: 17.088

2.  C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies.

Authors:  Joshua T Geiger; Karissa C Arthur; Ted M Dawson; Liana S Rosenthal; Alexander Pantelyat; Marilyn Albert; Argye E Hillis; Barbara Crain; Olga Pletnikova; Juan C Troncoso; Sonja W Scholz
Journal:  Neurodegener Dis       Date:  2016-05-31       Impact factor: 2.977

3.  C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis.

Authors:  Micaela Fredi; Ilaria Cavazzana; Giorgio Biasiotto; Massimiliano Filosto; Alessandro Padovani; Eugenio Monti; Angela Tincani; Franco Franceschini; Isabella Zanella
Journal:  Neuromolecular Med       Date:  2019-03-11       Impact factor: 3.843

Review 4.  Expanding Clinical Spectrum of C9ORF72-Related Disorders and Promising Therapeutic Strategies: A Review.

Authors:  Sarah Breevoort; Summer Gibson; Karla Figueroa; Mark Bromberg; Stefan Pulst
Journal:  Neurol Genet       Date:  2022-04-29

Review 5.  C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature.

Authors:  Thomas Bourinaris; Henry Houlden
Journal:  Mov Disord Clin Pract       Date:  2018-11-08

6.  Clinical Update on C9orf72: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Beyond.

Authors:  Dario Saracino; Isabelle Le Ber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Intermediate C9orf72 alleles in neurological disorders: does size really matter?

Authors:  Adeline S L Ng; Eng-King Tan
Journal:  J Med Genet       Date:  2017-07-08       Impact factor: 6.318

Review 8.  Recent advances in amyotrophic lateral sclerosis.

Authors:  Nilo Riva; Federica Agosta; Christian Lunetta; Massimo Filippi; Angelo Quattrini
Journal:  J Neurol       Date:  2016-03-30       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.